Neuroblastoma spans a wider range of outcomes than almost any other pediatric malignancy. Half of cases are classified as high-risk, and that subset drives most of the field's research and treatment-intensity decisions. The clinical challenge is calibrating what curative intent demands at each decision point across a heterogeneous disease spectrum.
Curative ambition translates into concrete action at three inflection points. Risk group assignment at diagnosis sets the baseline plan. Response-guided protocol adaptation refines it during induction and consolidation. Goal reassessment at incomplete response or relapse defines the next phase of care. The third node, where many high-risk patients eventually arrive, has shifted since DANYELZA's accelerated approval introduced a targeted option for relapsed or refractory disease in the bone or bone marrow.
Decision Node 1: Risk Group Assignment and Neuroblastoma Treatment Intensity Calibration
The first and most consequential decision is matching intensity to biology. Overtreating a low-risk patient exposes them to needless late effects. Undertreating a high-risk patient forfeits the best window for cure. The 2021 Children's Oncology Group classifier, version 2, is the operative standard for this calibration. It incorporates the INRG Staging System and segmental chromosomal aberrations alongside MYCN, histology, and ploidy.
Half of neuroblastoma is classified as high-risk. The risk assignment determines treatment intensity across the entire disease course. Low-risk patients require observation or surgery, with chemotherapy rarely needed.
Intermediate-risk patients require surgery and time-limited chemotherapy. High-risk patients require the full multimodal sequence of induction, surgery, tandem autologous stem cell transplant, radiation, and anti-GD2 immunotherapy maintenance.
Two classifier-specific nuances are operationally important. Version 2 incorporates segmental chromosomal aberrations at 1p and 11q, which reassigns a subset of patients previously classified as intermediate-risk under version 1 to high-risk. The classifier also uses INRG Staging System pretreatment imaging rather than surgical staging, meaning image-defined risk factor assessment at diagnosis directly informs risk assignment.
Centers using version 1 criteria should verify alignment with version 2 before protocol enrollment. The reclassification flows in both directions, with some patients moving down as well as up. Active trial eligibility depends on the current classifier, and version mismatch creates downstream enrollment problems.
Bone and bone marrow involvement at staging carries downstream therapeutic implications. Among patients with metastatic disease, 70 percent of metastases involve bone marrow and 55 percent involve cortical bone. The pattern at initial staging predicts which patients will be candidates for therapies indicated specifically for bone or bone marrow involvement at relapse.
Decision Node 2: Response-Guided Protocol Adaptation
The risk group sets the treatment plan. The end-of-induction response refines it. In high-risk disease, induction response is an independent prognostic variable that shapes both biological trajectory and eligibility for protocol modification. Two-thirds of patients do not achieve a complete metastatic response during induction, which makes response assessment a routine decision point rather than an exceptional one.
The Curie scoring system is the validated quantitative framework for MIBG-based response assessment. The body is subdivided into 10 regions, nine skeletal and one soft tissue, each scored 0 to 3 for a maximum collective score of 30. An absolute Curie score of 0 to 2 prior to transplant is more clinically prognostic than relative reduction in score from baseline.
Assessment of bone and bone marrow disease requires both MIBG imaging and biopsy. The combined approach captures the compartment-level picture that single modalities miss. Curie scoring requires 123I-MIBG imaging and scoring against the 10-segment anatomic map. Institutions should confirm their nuclear medicine protocols use 123I rather than 131I for response imaging.
The clinical decision framework at end of induction follows the Curie score. An absolute score of 2 or less, with adequate bone marrow clearance, supports proceeding with planned consolidation. A score above 2 supports consideration of intensified or alternative strategies and evaluation of clinical trial eligibility before consolidation.
A second response-decision node occurs after consolidation and stem cell transplant, before maintenance immunotherapy. Patients proceeding to anti-GD2 maintenance should have documented disease response or control at this point. Two-fifths of patients relapse despite intensive multimodal frontline therapy, which means the post-consolidation reassessment is not a formality.
Decision Node 3: Naxitamab Eligibility and Timing in Relapsed or Refractory Neuroblastoma
For high-risk patients who relapse or prove refractory, curative intent must be reassessed against a more constrained evidence base. The availability of an FDA-approved therapy targeting residual disease in the bone or bone marrow has changed the clinical calculus at this point. Relapse no longer automatically shifts goals from cure to palliation.
DANYELZA
DANYELZA (naxitamab-gqgk), in combination with GM-CSF, is indicated for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Eligible patients must have demonstrated a partial response, minor response, or stable disease to prior therapy. Active disease progression is an exclusion. Severe hypersensitivity to naxitamab-gqgk, including anaphylaxis, is a contraindication, and uncontrolled hypertension must be managed before initiation.
The timing question in relapsed and refractory disease is whether the patient has reached a disease state that matches the indication. The pivotal Study 201 initial analysis included 22 efficacy-evaluable patients, with an overall response rate of 45 percent, complete responses in 36 percent, and partial responses in 9 percent.
The pre-specified interim analysis expanded the efficacy population to 52 patients, with an overall response rate of 40 percent, complete responses in 29 percent, and partial responses in 11 percent. Among 26 patients with incomplete response to induction therapy, the overall response rate was 46 percent. Among 26 patients with incomplete response to relapse therapy, it was 35 percent.
Median cycles completed in the Study 201 pre-specified interim analysis was seven, with 50 percent of patients receiving seven or more cycles. The figures apply specifically to patients matching the trial eligibility criteria, not to the broader relapsed population. Stretching the data to patients with soft tissue-only disease or active progression overreaches the evidence base.
The accelerated approval rests on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Population matching at this decision node is the discipline that separates evidence-based eligibility decisions from hopeful extrapolation. Tumor board review at every relapse reassessment helps identify both label eligibility and trial enrollment options.
Communication Principles for a Curative-Intent Framework
A clinical framework for curative intent has two beneficiaries. The treatment team uses it for protocol decisions. Families use it to track expectations against the evidence. The two audiences need different things from the same data, and the clinical encounter serves both.
Survival statistics by risk group are population-level estimates, not individual predictions. Presenting them as probability ranges rather than fixed outcomes gives families a more accurate picture. The framing preserves both honesty and hope without flattening either.
The distinction between overall survival and event-free survival also matters in clinical conversations. A child who relapsed and was retreated may be alive at five years but is not in the event-free survival denominator. Explaining what each measure captures helps families interpret the numbers they will encounter elsewhere.
Clinicians should also surface the accelerated approval framing where it applies. For patients considering DANYELZA, the indication rests on overall response rate and duration of response from single-arm trials, with continued approval potentially contingent on confirmatory data. Naming the evidence structure honestly is part of the curative-intent conversation, not separate from it.
Apply the Curative-Intent Framework to Your Patient Population
Curative intent in neuroblastoma translates into concrete action at three decision nodes. Risk group assignment at diagnosis sets the trajectory. Response-guided adaptation refines it through induction and consolidation. Eligibility assessment at relapse defines what targeted options are appropriate. The 2021 classifier, the Curie scoring system, and the DANYELZA indication criteria together define the evidence base.
Full prescribing information, clinical decision support, and HCP resources for DANYELZA are available at DanyelzaHCP.com.
Sources
- DANYELZA (naxitamab-gqgk) [package insert]. New York, NY: Y-mAbs Therapeutics, Inc.; 2024. https://labeling.ymabs.com/danyelza
- Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580-2587. https://pubmed.ncbi.nlm.nih.gov/28471719/
- DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21(3):181-189. https://pubmed.ncbi.nlm.nih.gov/10363850/
- Garaventa A, Poetschger U, Valteau-Couanet D, et al. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021;39(23):2552-2563. https://ascopubs.org/doi/10.1200/JCO.20.03144
- Pinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children's Oncology Group. Eur J Cancer. 2019;112:66-79.
- Yanik GA, Parisi MT, Naranjo A, et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59(3):502-508. https://jnm.snmjournals.org/content/59/3/502
- Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. J Nucl Med. 2013;54(4):541-548. https://jnm.snmjournals.org/content/54/4/541
